

PROF. ALBERTO CORSINI

CURRICULUM VITAE

Personal data

Date of birth: December 5, 1958

Place of birth: Milan, Italy

Nationality: Italian

Mailing address: Department of Pharmacological and Biomolecular Sciences
University of Milan
Via Balzaretti 9
20133 Milan, Italy

Education

1977 Student in Pharmacy, University of Milan, Italy

1981 Doctor in Pharmacy, "Magna cum Laude", University of Milan, Italy

1983 Ph.D. in "Experimental Pharmacology" at the University of Milan, Italy

1990 Ph.D. in "Experimental Medicine: Atherosclerosis" at the University of Siena, Italy

Present Appointment: October 1st, 2017

Director Dept. of Pharmacological and Biomolecular Sciences
University of Milan, Italy – Full Professor of Pharmacology

Positions held:

1981 – 1985 Postdoctoral Researcher, Laboratory of Cellular Pharmacology of Atherosclerosis, Institute of Pharmacological Sciences, University of Milan, Italy

1986 – 1987 Postdoctoral Fellow, Gladstone Foundation Laboratories for Cardiovascular Disease, Cardiovascular Research Institute, Department of Pathology and Medicine, University of California, San Francisco, USA

1988 – 1990 Fellow of the Institute of Pharmacological Sciences, University of Milan, Italy

1990 – 1997 Assistant Professor of Pharmacology, Institute of Pharmacological Sciences, University of Milan, Italy

1993 – 1999	Visiting Scientist, Department of Biochemistry (Howard Hughes Medical Institute), University of Washington, Seattle, USA
1998 – 2004	Associate Professor of Pharmacology, Institute of Pharmacological Sciences, University of Milan, Italy
2005 to date	Full Professor of Pharmacology, Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy
2017	Director Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy

HONORS, SCOLARSHIPS, FELLOWSHIPS

1998	Selected winner of an International Atherosclerosis Society Visiting Fellowship
1985 - 1989	PhD Student in "Experimental Medicine: Atherosclerosis" University of Siena directed by Prof. G. Weber
1984 - 1985	Postdoctoral fellowship of the Nutrition Foundation of Italy
1983 - 1985	Fellow of the Institute of Pharmacological Sciences, University of Milan.

MEMBER OF THE EDITORIAL BOARD

- CLINICAL THERAPEUTICS
- CARDIOVASCULAR DRUG AND THERAPY
- PHARMACOLOGICAL RESEARCH
- CANCER AND AGING
- SISTEMA UNIVERSITÀ
- EUROPEAN CARDIOLOGY
- CANCER AND AGING

MOST RECENT PUBLICATIONS

Ferri N, Corsini A, Sirtori C, Ruscica M. PPAR- α agonists are still on the rise: an update on clinical and experimental findings. *Expert Opin Investig Drugs*. 2017 May; 26(5):593-602

Ferri N, Corsini A, Sirtori CR, Ruscica M. Bococizumab for the treatment of hypercholesterolaemia. *Expert Opin Biol Ther*. 2017

Corsini A. Low-density lipoprotein cholesterol variability increases the risk of cardiovascular events: the importance of keeping constant low cholesterol levels. *J Cardiovasc Med (Hagerstown)*. 2017 Jan;18 Suppl 1: Special Issue on The State of the Art for the Practicing Cardiologist: The 2016 Conoscere E Curare Il Cuore (CCC) Proceedings from the CLI Foundation:e91-e93

Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Ž, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WM, Vlachopoulos C, Wood DA, Zamorano JL; Authors/Task Force Members; Additional Contributor. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. *Eur Heart J*. 2016 Oct 14;37(39):2999-3058

Apostolopoulou M, Corsini A, Roden M The role of mitochondria in statin-induced myopathy.. Eur J Clin Invest. 2015 Jul;45(7):745-54. I.F. 2.59

European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel Statin-associated muscle symptoms: impact on statin therapy-. Eur Heart J. 2015 May 1;36(17):1012-22. IF. 15.203

Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Ceška R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, da Silva PM, Masana L, Odawara M, Pedersen TR, Rotella CM, Salti I, Teramoto T, Tokgozoglul L, Toth PP, Valensi P, Vergès B. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice Atheroscler Suppl. 2014 Jun;15(1):1-15. IF: 2.293

Ferri N, Corsini A. Clinical evidence of statin therapy in non-dyslipidemic disorders. Ferri N, Corsini A. Pharmacol Res. 2014 IF 4.436.

Publications

- 1) Inhibitory effect of PCSK9 on ABCA1 protein expression and cholesterol efflux in macrophages. Adorni MP, Cipollari E, Favari E, Zanotti I, Zimetti F, Corsini A, Ricci C, Bernini F, Ferri N. Atherosclerosis. 2017; 256:1-6. IF: 4.239
- 2) ABCA1 and HDL3 are required to modulate smooth muscle cells phenotypic switch after cholesterol loading. Castiglioni S, Monti M, Arnaboldi L, Canavesi M, Ainis Buscherini G, Calabresi L, Corsini A, Bellosta S. Atherosclerosis. 2017; 266:8-15 IF: 4.239
- 3) Increased PCSK9 Cerebrospinal Fluid Concentrations in Alzheimer's Disease. Zimetti F, Caffarra P, Ronda N, Favari N, Adorni MP, Zanotti I, Bernini F, Barocco F, Spallazzi M, Galimberti D, Ricci C, Ruscica M, Corsini A, e Ferri N. Journal of Alzheimer's Disease. 2016; 55: 315-320. IF: 3.920
- 4) PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement. Ferri N, Marchianò S, Tibolla G, Baetta R, Dhyani A, Ruscica M, Uboldi P, Catapano A.L., Corsini A. Atherosclerosis. 2016; 253: 214-224. IF: 4.239
- 5) Geranylgeraniol prevents the simvastatin-induced PCSK9 expression: role of the small G protein Rac1. Ferri N, Marchianò S, Lupo MG, Trenti A, Biondo G, Castaldello P, and Corsini A. Pharmacol Res. 2017. 122: 96-104. IF: 4.816
- 6) PCSK9 antagonists and inflammation. Ruscica M, Ferri N, Corsini A And Sirtori C.R. Atherosclerosis. 2017 (In Press). IF: 4.239.
- 7) Proprotein convertase subtilisin kexin type 9 and high-density lipoprotein metabolism: experimental animal models and clinical evidence. Ferri N, Corsini A, Macchi C, Magni P, Ruscica M. Transl Res. 2015 Oct 20. pii: S1931-5244(15)00345-X. IF 5.030
- 8) Human megakaryocytes confer tissue factor to a subset of shed platelets to stimulate thrombin generation. Brambilla M, Facchinetti L, Canzano P, Rossetti L, Ferri N, Balduini A, Abbonante V, Boselli D, De Marco L, Di Minno MN, Toschi V, Corsini A, Tremoli E, Camera M. Thromb Haemost. 2015 Aug 31;114(3):579-92. I.F. 5.760

- 9) The role of mitochondria in statin-induced myopathy. Apostolopoulou M, Corsini A, Roden M. *Eur J Clin Invest.* 2015 Jul;45(7):745-54
- 10) Fibronectin extra domain A stabilises atherosclerotic plaques in apolipoprotein E and in LDL-receptor-deficient mice. Pulakazhi Venu VK, Uboldi P, Dhyani A, Patrini A, Baetta R, Ferri N, Corsini A, Muro AF, Catapano AL, Norata GD. *Thromb Haemost.* 2015 Jul;114(1):186-97. I.F. 5.760
- 11) Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. Baetta R, Lento S, Ghilardi S, Barbati E, Corsini A, Tremoli E, Banfi C. *Vascul Pharmacol.* 2015 Apr-Jun;67-69:38-47. IF. 3.635
- 12) Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. *Eur Heart J.* 2015 May 1;36(17):1012-22. IF. 15.203
- 13) Suppressor of Cytokine Signaling-3 (SOCS-3) Induces Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Expression in Hepatic HepG2 Cell Line. Ruscica M, Ricci C, Macchi C, Magni P, Cristofani R, Liu J, Corsini A, Ferri N. *J Biol Chem.* 2016 Feb 12;291(7):3508-19. IF: 4.573
- 14) Aliskiren inhibits prorenin-induced human aortic smooth muscle cell migration. Ferri N, Panariti F, Ricci C, Maiocchi G, Corsini A. *J Renin Angiotensin Aldosterone Syst.* 2015 Jun;16(2):284-91. IF: 2.286
- 15) The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Češka R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, da Silva PM, Masana L, Odawara M, Pedersen TR, Rotella CM, Salti I, Teramoto T, Tokgozoglul L, Toth PP, Valensi P, Vergès B. *Atheroscler Suppl.* 2014 Jun;15(1):1-15. IF: 2.293
- 16) Farnesyltransferase inhibitors: CAAX mimetics based on different biaryl scaffolds . Straniero V., Pallavicini M., Chiodini G., Ruggeri P., Fumagalli L., Bolchi C., Corsini A., Ferri N., Ricci C., Valoti E. *Bioorganic and Medicinal Chemistry Letters* 2014; 24: 2924-7. I.F.2.650
- 17) 2-Amino-3-(phenylsulfanyl)norbornane-2-carboxylate: An appealing scaffold for the design of Rac1-Tiam1 protein-protein interaction inhibitors Ruffoni A., Ferri N., Bernini S.K., Ricci C., Corsini A., Maffucci I., Clerici F., Contini A. *Journal of Medicinal Chemistry* 2014; 57: 2953-62. IF: 5.614
- 18) Cigarette smoke condensate affects monocyte interaction with endothelium. Giunzioni I., Bonomo A., Bishop E., Castiglioni S., Corsini A., Bellosta S. *Atherosclerosis* 2014; 234: 383-90 IF: 3.706
- 19) Cyclosporine A Impairs the Macrophage Reverse Cholesterol Transport in Mice by Reducing Sterol Fecal Excretion. Zanotti I., Greco D., Lusardi G., Zimetti F., Poti F., Arnaboldi L., Corsini A., Bernini F. *PLoS ONE* 2013; 8: e71572 IF. 3.534
- 20) Nitric oxide-donating atorvastatin attenuates neutrophil recruitment during vascular inflammation independent of changes in plasma cholesterol Baetta R., Granata A., Miglietta D., Oliva F., Arnaboldi L., Bonomo A., Ferri N., Ongini E., Bellosta S., Corsini A. *Cardiovascular Drugs and Therapy* 2013; 27: 211-9 IF: 3.130

- 21) 3-Aryl-N-aminosulfonylphenyl-1H-pyrazole-5-carboxamides: A new class of selective Rac inhibitors. Ferri N., Bernini S.K., Corsini A., Clerici F., Erba E., Stragliotto S., Contini A. *MedChemComm* 2013; 4: 537-541 IF: 2.722
- 22) Chemotactic effect of prorenin on human aortic smooth muscle cells: A novel function of the (pro)renin receptor. Greco C.M., Camera M., Facchinetti L., Brambilla M., Pellegrino S., Gelmi M.L., Tremoli E., Corsini A., Ferri N. *Cardiovascular Research*. 2012; 95: 366-74 IF: 5.940
- 23) Upregulation of lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) expression in human endothelial cells by modified high density lipoproteins. Pirillo A., Uboldi P., Ferri N., Corsini A., Kuhn H., Catapano A.L. *Biochemical and Biophysical Research Communications* 2012; 428: 230-3 IF: 2.484
- 24) Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levels. Ferri N., Tibolla G., Pirillo A., Cipollone F., Mezzetti A., Pacia S., Corsini A., Catapano A.L. *Atherosclerosis* 2012; 220: 381-6 IF: 3.706
- 25) Aliskiren reduces prorenin receptor expression and activity in cultured human aortic smooth muscle cells. Ferri N., Greco C.M., Maiocchi G., Corsini A. *JRAAS - Journal of the Renin-Angiotensin-Aldosterone System* 2011; 12: 469-74 IF: 2.439
- 26) Synthesis, structural, and biological evaluation of bis- heteroarylmaleimides and bis-heterofused imides. Ferri N., Radice T., Antonino M., Beccalli E.M., Tinelli S., Zunino F., Corsini A., Pratesi G., Ragg E.M., Gelmi M.L., Contini A. *Bioorganic and Medicinal Chemistry* 2011;19: 5291-9. IF: 2.969
- 27) Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase Bolchi C., Pallavicini M., Bernini S.K., Chiodini G., Corsini A., Ferri N., Fumagalli L., Straniero V., Valoti E. *Bioorganic and Medicinal Chemistry Letters* 2011; 21: 5408-12. IF:2.661
- 28) Free cholesterol alters macrophage morphology and mobility by an ABCA1 dependent mechanism Adorni M.P., Favari E., Ronda N., Granata A., Bellosta S., Arnaboldi L., Corsini A., Gatti R., Bernini F. *Atherosclerosis* 2011; 215: 70-6. IF: 3.794
- 29) Upregulation of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells Pirillo A., Reduzzi A., Ferri N., Kuhn H., Corsini A., Catapano A.L. *Atherosclerosis* 2011; 214:331-7 IF: 3.794
- 30) Increased atherosclerosis and vascular inflammation in APP transgenic mice with apolipoprotein E deficiency. Tibolla G., Norata G.D., Meda C., Arnaboldi L., Uboldi P., Piazza F., Ferrarese C., Corsini A., Maggi A., Vegeto E., Catapano A.L. *Atherosclerosis* 2010;210: 78-87. IF: 3.794
- 31) Synthetic peptides containing a conserved sequence motif of the Id protein family modulate vascular smooth muscle cell phenotype. Pellegrino S., Ferri N., Colombo N., Cremona E., Corsini A., Fanelli R., Gelmi M.L., Cabrele C. *Bioorganic and Medicinal Chemistry Letters*. 2009; 19:6298-302. I.F. 2.650
- 32) Fibrillar collagen inhibits cholesterol biosynthesis in human aortic smooth muscle cells. Ferri N., Roncalli E., Arnaboldi L., Fenu S., Andrukhova O., Aharinejad S., Camera M., Tremoli E., Corsini A. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2009; 29: 1631-7 I.F. 7.235
- 33) New Ras CAAX mimetics: Design, synthesis, antiproliferative activity, and RAS prenylation inhibition. Bolchi C., Pallavicini M., Fumagalli L., Ferri N., Corsini A., Rusconi C., Valoti E. *Bioorganic and Medicinal Chemistry Letters* 2009; 19: 5500-4. . I.F.2.650
- 34) Virtual screening approach for the identification of new Rac1 inhibitors. Ferri N., Corsini A., Bottino P., Clerici F., Contini A. *Journal of Medicinal Chemistry* 2009; 52: 4087-90 . I.F. 4.802

- 35) Everolimus inhibits monocyte/macrophage migration in vitro and their accumulation in carotid lesions of cholesterol-fed rabbits. Baetta R., Granata A., Canavesi M., Ferri N., Arnaboldi L., Bellosta S., Pfister P., Corsini A. *Journal of Pharmacology and Experimental Therapeutics* 2009; 328: 419-25 . I.F. 4.309
- 36) Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/ cyclin E expression. Ferri N., Granata A., Pirola C., Torti F., Pfister P.J., Dorent R., Corsini A. *Molecular Pharmacology* 2008; 74: 144-53 I.F 4.711
- 37) Antiproliferative effects on human tumor cells and rat aortic smooth muscular cells of 2,3-heteroarylmaleimides and heterofused imides. Ferri N., Beccalli E.M., Contini A., Corsini A., Antonino M., Radice T., Pratesi G., Tinelli S., Zunino F., Gelmi M.L. *Bioorganic and Medicinal Chemistry* 2008; 16: 1691-701. IF 2.624
- 38) Serum from hypercholesterolemic patients treated with atorvastatin or simvastatin inhibits cultured human smooth muscle cell proliferation. Arnaboldi L., Guzzetta M., Pazzucconi F., Radaelli G., Paoletti R., Sirtori C.R., Corsini A. *Pharmacological Research* 2007; 56: 503-8 IF 2.421
- 39) Peptidomimetic inhibitors of farnesyltransferase with high in vitro activity and significant cellular potency. Bolchi C., Pallavicini M., Rusconi C., Diomede L., Ferri N., Corsini A., Fumagalli L., Pedretti A., Vistoli G., Valoti E. *Bioorganic and Medicinal Chemistry Letters* 2007; 17: 6192-6. IF 2.538
- 40) Perivascular carotid collar placement induces neointima formation and outward arterial remodeling in mice independent of apolipoprotein E deficiency or Western-type diet feeding. Baetta R., Silva F., Comparato C., Uzzo M., Eberini I., Bellosta S., Donetti E., Corsini A. *Atherosclerosis* 2007;195: e112–e124 IF 3.811
- 41) Raloxifene inhibits matrix metalloproteinases expression and activity in macrophages and smooth muscle cells. Bellosta S., Baetta R., Canavesi M., Comparato C., Granata A., Monetti M., Cairoli F., Eberini I., Puglisi L., Corsini A. *Pharmacological Research* 2007; 56: 160-7 IF 2.421
- 42) Rosuvastatin displays anti-atherothrombotic and anti-inflammatory properties in apoE-deficient mice. Monetti M., Canavesi M., Camera M., Parente R., Paoletti R., Tremoli E., Corsini A., Bellosta S. *Pharmacological Research*. 2007; 55: 441-9 IF 2.42
- 43) Simvastatin reduces MMP1 expression in human smooth muscle cells cultured on polymerized collagen by inhibiting Rac1 activation Ferri N., Colombo G., Ferrandi C., Raines E.W., Levkau B., Corsini A. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2007; 27: 1043-9. IF 6.883
- 44) Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta Pinna C., Bolego C., Sanvito P., Pelosi V., Baetta R., Corsini A., Gaion R.M., Cignarella A. *Journal of Pharmacology and Experimental Therapeutics* 2006; 319: 1444-51 (IF 3.956)
- 45) Isothiazoles. Part XV. A mild and efficient synthesis of new antiproliferative 5-sulfanylsubstituted 3-alkylaminoisothiazole 1,1-dioxides Clerici F., Contini A., Corsini A., Ferri N., Grzesiak S., Pellegrino S., Sala A., Yokoyama K. *European Journal of Medicinal Chemistry*. 2006; 41: 675-82 IF 2.187
- 46) Isothiazole dioxide derivative 6n inhibits vascular smooth muscle cell proliferation and protein farnesylation Ferri N., Clerici F., Yokoyama K., Pocar D., Corsini A. *Biochemical Pharmacology*. 2005; 70: 1735-43 IF 3.581
- 47) PPAR α inhibits vascular smooth muscle cell proliferation underlying intimal hyperplasia by inducing the tumor suppressor p16INK4a Gizard F., Amant C., Barbier O., Bellosta S., Robillard R., Percevault F., Sevestre H., Krimpenfort P., Corsini A., Rochette J., Glineur C., Fruchart J.-C., Torpier G., Staels B. *Journal of Clinical Investigation* 2005; 115: 3228-38. IF 15.754

- 48) Clinical and biochemical characterisation of patients with autosomal recessive hypercholesterolemia (ARH). R. Fellin, G. Zuliani, M. Arca, P. Pintus, A. Pacifico, A. Montali, A. Corsini, M. Maioli. *Nutr Metab Cardiovasc Dis* 2003;13:278-286 (IF 2.148)
- 49) Dysfunction of the cholesterol biosynthetic pathway in Huntington's disease. Valenza M., Rigamonti D., Goffredo D., Zuccato C., Fenu S., Jamot L., Strand A., Tarditi A., Woodman B., Racchi M., Mariotti C., Di Donate S., Corsini A., Bates G., Pruss R., Olson J.M., Sipione S., Tartari M., Cattaneo E. *Journal of Neuroscience* 2005; 25: 9932-9. IF 7.453
- 50) Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation Ferri N., Yokoyama K., Sadilek M., Paoletti R., Apitz-Castro R., Gelb M.H., Corsini A. *British Journal of Pharmacology* 2003; 138: 811-818 IF 3.611
- 51) Autosomal recessive hypercholesterolemia in a Sicilian kindred harboring the 432insA mutation of the ARH gene Barbagallo C.M., Emmanuele G., Cefalu A.B., Fiore B., Noto D., Mazzarino M.C., Pace A., Brogna A., Rizzo M., Corsini A., Notarbartolo A., Travali S., Averna M.R. *Atherosclerosis* 2003; 166: 395-400 I.F. 3.603
- 52) Polymorphonuclear leukocyte-myocyte interaction: an early event in collar-induced rabbit carotid intimal. Donetti E, Baetta R, Comparato C, Altana C, Sartore S, Paoletti R, Castano P, Gabbiani G, Corsini A. *Experimental Cells Research* 2002;274:197-206 (I.F. 3.949)
- 53) Italian familial defective apolipoprotein B patients share a unique haplotype with other Caucasian patients. AB Cefalù, CM Barbagallo, E Sesti, R Caldarella, F Polizzi, G Marino, D Noto, M Rolleri, S Travali, G Scalisi, A Notarbartolo, A Corsini, S Bertolini, MR Averna *Clinical and Experimental Medicine* 2001;1:151-154 (IF 0.906)
- 54) Effect of S(-) perillic acid on protein prenylation and arterial smooth muscle cell proliferation Ferri N., Arnaboldi L., Orlandi A., Yokoyama K., Gree R., Granata A., Hachem A., Paoletti R., Gelb M.H., Corsini A. *Biochemical Pharmacology*. 2001; 62: 1637-1645. I.F. 2.993
- 55) Phenotypic heterogeneity influences apoptotic susceptibility to retinoic acid and cis-platinum of rat arterial smooth muscle cells in vitro implications for the evolution of experimental intimal thickening Orlandi A., Francesconi A., Cocchia D., Corsini A., Spagnoli L.G. *Arteriosclerosis, Thrombosis, and Vascular Biology* 2001; 21: 1118-23. (I.F. 5.816)
- 56) Effect of valsartan on angiotensin II-induced plasminogen activator inhibitor-1 biosynthesis in arterial smooth muscle cells Sironi L., Calvio A.M., Arnaboldi L., Corsini A., Parolari A., De Gasparo M., Tremoli E., Mussoni L. *Hypertension*. 2001; 37: 961-966 I.F. 5.630
- 57) Picotamide, an antithromboxane agent, inhibits the migration and proliferation of arterial myocytes Ratti S., Quarato P., Casagrande C., Fumagalli R., Corsini A. *European Journal of Pharmacology* 1998; 355: 77-83 I.F. 2.351
- 58) Direct effects of statins on the vascular wall. Corsini A, Pazzucconi F, Arnaboldi L, Pfister P, Fumagalli R, Paoletti R, Sirtori CR J. *Cardiovasc. Pharmacol.* 1998; 31: 773-778. (I.F. 1,476)
- 59) Pharmacological control of the mevalonate pathway: Effect on arterial smooth muscle cell proliferation Raiteri M., Arnaboldi L., Mcgeady P., Gelb M.H., Verri D., Tagliabue C., Quarato P., Ferraboschi P., Santaniello E., Paoletti R., Fumagalli R., Corsini A. *Journal of Pharmacology and Experimental Therapeutics* 1997; 281: I.F. 3,432
- 60) Effect of the new calcium antagonist lercanidipine and its enantiomers on the migration and proliferation of arterial myocytes Corsini A., Bonfatti M., Quarato P., Accomazzo M.R., Raiteri M., Sartani A., Testa R., Nicosia S., Paoletti R., Fumagalli R. *Journal of Cardiovascular Pharmacology* 1996; 28: 687-694. I.F. 1,476

- 61) Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes Corsini A., Arnaboldi L., Raiteri M., Quarato P., Faggiotto A., Paoletti R., Fumagalli R. *Pharmacological Research* 1996; 33: 55-61. I.F. 0,315
- 62) Severe hypercholesterolemia: unusual inheritance in an italian pedigree. Zuliani G, Vigna GB, Corsini A, Maioli M, Romagnoli F, Fellin R *Eur. J. Clin. Invest.*, 1995; 25: 322-331. I.F. 2,224
- 63) Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation Vigano T., Hernandez A., Corsini A., Granata A., Belloni P., Fumagalli R., Paoletti R., Folco G. *European Journal of Pharmacology: Molecular Pharmacology* 1995; 291: 201-203. I.F. 2,677
- 64) Effects of 26-aminocholesterol, 27-hydroxycholesterol, and 25-hydroxycholesterol on proliferation and cholesterol homeostasis in arterial myocytes Corsini A., Verri D., Raiteri M., Quarato P., Paoletti R., Fumagalli R. *Arteriosclerosis, Thrombosis, and Vascular Biology* 1995; 15: 420-428. I.F. 5,102
- 65) Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs: An LDL receptor-independent phenomenon Tremoli E., Camera M., Maderna P., Sironi L., Prati L., Colli S., Piovello F., Bernini F., Corsini A., Mussoni L. *Arteriosclerosis, Thrombosis, and Vascular Biology* 1993; 13: 338-346. I.F. 5,158
- 66) 27-Hydroxycholesterol modulation of low density lipoprotein metabolism in cultured human hepatic and extrahepatic cells Bellosta S., Corsini A., Bernini F., Granata A., Didoni G., Mazzotti M., Fumagalli R. *FEBS Letters* 1993; 332: 115-118. I.F. 3,339
- 67) Relationship between mevalonate pathway and arterial myocyte proliferation: in vitro studies with inhibitors of HMG-CoA reductase Corsini A., Mazzotti M., Raiteri M., Soma M.R., Gabbiani G., Fumagalli R., Paoletti R. *Atherosclerosis* 1993; 101: 117-125. I.F. 3,306
- 68) Alternative splicing of mutant LDL-receptor mRNA in an italian patient with familial hypercholesterolemia. The safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions a due to a partial deletion of LDL-receptor gene (FH^{POTENZA}). Lelli N, Garuti R, Zambelli F, Cassanelli S, Tiozzo R, Corsini A, Bertolini S, Riva E, Ortisi MT, Bellu R, Calandra S *J. Lipid Res.*, 1993; 34: 1347-1354. I.F. 3,774
- 69) Effect of the nifedipine-atenolol association on arterial myocyte migration and proliferation Corsini A., Quarato P., Raiteri M., Paubert-Braquet M., Nguyen G., Picquot S., Bourgain R.H., Fumagalli R., Paoletti R. *Pharmacological Research* 1993; 27: 299-307. I.F. 0,259
- 70) Ability of the LDL receptor from several animal species to recognize the human apo B binding domain: studies with LDL from familial defective apo B-100 Corsini A., Mazzotti M., Villa A., Maggi F.M., Bernini F., Romano L., Romano C., Fumagalli R., Catapano A.L. *Atherosclerosis* 1992; 93: 95-103. I.F. 2,919
- 71) Monoclonal antibodies to human low density lipoprotein identify distinct areas on apolipoprotein B-100 relevant to the low density lipoprotein- receptor interaction Fantappie S., Corsini A., Sidoli A., Uboldi P., Granata A., Zanelli T., Rossi P., Marcovina S., Fumagalli R., Catapano A.L. *Journal of Lipid Research*. 1992; 33: 1111-1121. I.F. 3,285
- 72) Low density lipoprotein receptor activity is modulated by soybean globulins in cell culture Lovati M.R., Manzoni C., Corsini A., Granata A., Frattini R., Fumagalli R., Sirtori C.R. *Journal of Nutrition* 1992; 122: 1971-1978. I.F. 1,713
- 73) Influence of trapidil and derivatives on cholesterol synthesis and esterification in cultured cells Beitz J., Corsini A., Bellosta S., Bernini F., Fumagalli R., Mest H.J., Paoletti R. *Pharmacological Research* 1991; 24: :235-42. (I.F. 0,418)

- 74) Cholesterol stimulation of HDL binding to human endothelial cells EAhy 926 and skin fibroblasts: evidence for a mechanism independent of cellular metabolism Bernini F., Bellosta S., Corsini A., Maggi F.M., Fumagalli R., Catapano A.L. *Biochimica et Biophysica Acta (BBA)/Lipids and Lipid Metabolism* 1991; 1083: 94-100. (I.F.2,460)
- 75) Simvastatin but not pravastatin inhibits the proliferation of rat aorta myocytes Corsini A., Raiteri M., Soma M., Fumagalli R., Paoletti R. *Pharmacological Research* 1991; 23: 173-180. (I.F. 0,418)
- 76) Poor response to simvastatin in familial defective apo B-100. A Corsini, M Mazzotti, R Fumagalli, AL Catapano, L Romano, C Romano. *The Lancet* 1991; 337: 305. (I.F. 15,871)
- 77) Familial defective apo B-100, characterization of an Italian family Corsini A., McCarthy B.J., Granata A., Soria L.F., Fantappie S., Bernini F., Romano C., Romano L., Fumagalli R., Catapano A.L. *European Journal of Clinical Investigation* 1991; 21: 389-397. I.F. 1,720
- 78) In vitro inhibition of arterial myocyte growth and stimulation of low density lipoprotein metabolism by SIM 6080, a new calcium antagonist Bernini F., Fantoni M., Corsini A., Fumagalli R. *Pharmacological Research* 1990; 22: 27-35 (IF: 0,710)
- 79) Trapidil derivatives and low density lipoprotein metabolism by human skin fibroblasts and by human hepatoma cell line Hep G2 Corsini A., Beitz J., Granata A., Fumagalli R., Mest H.-J., Paoletti R. *Pharmacological Research* 1989; 21: 521-531, 1989 I.F. 0,732
- 80) Monoclonal antibody 5A binds apolipoprotein B-48 and inhibits the low density lipoprotein-receptor interaction Corsini A., Fantappie S., Marcovina S., Granata A., Fumagalli R., Catapano A.L. *Biochemical and Biophysical Research Communications* 1989; 162: 908-15 (IF: 3.161)
- 81) Plasma lipoproteins and cholesterol metabolism in spontaneously hyperlipemic rats Fantappie S., Crestani M., Bosisio E., Galli G., Maggi F.M., Corsini A., Catapanoff A.L. *Atherosclerosis* 1989; 76: 3163-3171. (I.F. 2,183)
- 82) (5Z)-Carbacyclin displays agonist - antagonist properties on prostacyclin-receptors in platelets and vascular myocytes Corsini A., Oliva D., Folco G.C., Giovanazzi S., Noe' M.A., Fumagalli R., Nicosia S. *Biomedica Biochimica Acta* 1988; 47: 255-261. (I.F.4,173)
- 83) Progesterone modulates the expression of HDL binding sites in human skin fibroblasts Corsini A., Granata A., Bernini F., Maggi F.M., Fumagalli R., Catapano A.L. *Atherosclerosis* 1988;74: 1-2 113. (I.F. 1,941)
- 84) Lipophilic beta-adrenoceptor antagonists stimulate low density lipoprotein receptor activity in human skin fibroblasts Bernini F., Corsini A., Allorio M., Musanti R., Fumagalli R. *Pharmacology* 1987; 34: 34 225-232. (I.F. 1,132)
- 85) Regulation of low density lipoprotein metabolism by 26-hydroxycholesterol in human fibroblasts Lorenzo J.L., Allorio M., Bernini F., Corsini A., Fumagalli R. *FEBS Letters* 1987; 218: 77-80 (I.F. 3.341)
- 86) Lipophilic β -adrenoceptor antagonists stimulate cholesterol biosynthesis in human skin fibroblasts Corsini A., Bernini F., Cighetti G., Soma M., Galli G., Fumagalli R. *Biochemical Pharmacology* 1987; 36: 1901-1906. (I.F. 2,270)
- 87) (5Z)-carbacyclin discriminates between prostacyclin-receptors coupled to adenylate cyclase in vascular smooth muscle and platelets Corsini A., Folco G.C., Fumagalli R., Nicosia S., Noe M.A., Oliva D. *British Journal of Pharmacology* 1987; 90: 255-261. (I.F.4,173)

- 88) Autoantibodies to the low density lipoprotein receptor in a subject affected by severe hypercholesterolemia Corsini A., Roma P., Sommariva D., Fumagalli R., Catapano A.L. *Journal of Clinical Investigation* 1986; 78: 940-946. (I.F. 6,740)
- 89) Lack of correlation between TPA-induced prostaglandin biosynthesis and ornithine decarboxylase activity in BALB/c mouse 3T3 fibroblasts Tragni E., Corsini A., Fumagalli R., Flaminio L., Galli C.L. *Biochemical and Biophysical Research Communications* 1986; 139: 186-195. (I.F. 3,785)
- 90) Differential effects of in vitro ethanol on prostaglandin E1-sensitive adenylate cyclase from smooth muscle cells and platelets Noe M., Oliva D., Corsini A., Soma M., Fumagalli R., Nicosia S. *Journal of Cyclic Nucleotide and Protein Phosphorylation Research* 1985; 10: 293-308 (I.F. 4,030)
- 91) Nonprotein sulfhydryls as possible components of the protective effect of rosaprostol on the rat gastric mucosa Fumagalli R., Caponi R., Corsini A., Brambilla A., Palmira M., Bernini F., Valcavi U. *Prostaglandins* 1985; 29: 467-474. (I.F. 2,365)
- 92) In vitro inhibition of rat arterial smooth muscle cell growth by extractive sulfated mucopolysaccharides Musanti R., Bernini F., Corsini A., Soma M., Fumagalli R. *Pharmacological Research Communications* 1985; 17: 69-84 (I.F. 0,710)
- 93) 6-keto-prostaglandin E1-sensitive adenylate cyclase and binding sites in membranes from platelets and cultured smooth muscle cells Oliva D., Bernini F., Corsini A., Nicosia S. *Biochemical Pharmacology* 1984; 33: 3755-3758 (I.F. 2,295)
- 94) Experimental studies on the hypolipidemic activity of chloridarol Bernini F., Musanti R., Trezzi E., Corsini A., Fumagalli R., Meldolesi J., Catapano A.L. *Pharmacological Research Communications* 1983; 15: 201-215 (I.F. 0,796)

Review

- 1) Role of small GTPase protein Rac1 in cardiovascular diseases: development of new selective pharmacological inhibitors. Ferri N, Contini A, Bernini SK, Corsini A. *J Cardiovasc Pharmacol.* 2013; 62(5):425-35 IF 2.111
- 2) The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Sattar NA, Ginsberg H, Ray K, Chapman MJ, Arca M, Averna M, Betteridge DJ, Bhatnagar D, Bilianou E, Carmena R, Ceška R, Corsini A, Erbel R, Flynn PD, Garcia-Moll X, Gumprecht J, Ishibashi S, Jambart S, Kastelein JJ, Maher V, Marques da Silva P, Masana L, Odawara M, Pedersen TR, Rotella CM, Salti I, Teramoto T, Tokgozoglul L, Toth PP, Valensi P, Vergès B. *Atheroscler Suppl.* 2014
- 3) Clinical evidence of statin therapy in non-dyslipidemic disorders. Ferri N, Corsini A. *Pharmacol Res.* 2014 IF 4.436
- 4) Gender medicine: a task for the third millennium. Baggio G, Corsini A, Floreani A, Giannini S, Zagonel V. *Clin Chem Lab Med,* 51(4): 713-27, 2013
- 5) Drug-Induced Liver Injury: The role of drug metabolism and transport. Corsini A, Bortolini M. *J Clin Pharmacol* Feb. 22, 2013 IF 2.911

- 6) Current challenges and controversies in drug-induced liver injury. Corsini A, Ganey P, Ju C, Kaplowitz N, Pessayre D, Roth R, Watkins PB, Albassam M, Liu B, Stancic S, Suter L, Bortolini N. *Drug Saf*, 35 (12) 1099-117, 2012 IF 3.634
- 7) Drug attrition during pre-clinical and clinical development: understanding and managing drug-induced cardiotoxicity. Ferri N, Siegl P, Corsini A, Herrmann J, Lerman A, Benghozi R. *Pharmacol. Ther*, March 15th, 2013. (IF 8.652)
- 8) Statin drug interactions and related adverse reaction. Bellosta S, Corsini A. *Expert Opin Drug Saf*, 11 (6): 933-46, 2012 no IF
- 9) Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences. Baetta R, Corsini A. *Drugs*, 71 (11): 1441-67, 2011 (4.226)
- 10) Drug-drug interactions with statins: will pitavastatin overcome the statins' Achilles' heel? Corsini A, Ceska R. *Curr Med Res Opin*, 27 (8): 1551-62, 2011. No IF
- 11) Impact of diabetes mellitus on the clinical management of global cardiovascular risk: analysis of the results of the evaluation of final feasible effect of control training and ultra sensitization (EFFECTUS) Educational Program. Tocci G, Ferrucci A, Guida P, Avogaro A, Comaschi M, Corsini A, Cortese C, Giorda CB, Manzato E, Medea G, Mureddu GF, Riccardi G, Titta G, Ventriglia G, Zito GB, Volpe M. *Clin Cardiol*, 34 (9): 560-566, 2011. IF 1.807
- 12) An Analysis of the Management of Cardiovascular Risk Factors in Routine Clinical Practice in Italy: An Overview of the Main Findings of the EFFECTUS Study. Tocci G, Ferrucci A, Guida P, Avogaro A, Comaschi M, Corsini A, Cortese C, Giorda CB, Manzato E, Medea G, Mureddu GF, Riccardi G, Titta G, Ventriglia G, Zito GB, Volpe M. *High Blood Press Cardiovasc Prev*. 2011 Mar 1;18(1):19-30. noIF
- 13) Impact of physicians' age on the clinical management of global cardiovascular risk: analysis of the results of the Evaluation of Final Feasible Effect of Control training and ultrasensitisation educational programme. Tocci G, Ferrucci A, Guida P, Avogaro A, Comaschi M, Corsini A, Cortese C, Giorda CB, Manzato E, Medea G, Mureddu GF, Riccardi G, Titta G, Ventriglia G, Zito GB, Volpe M. *EFFECTUS Steering Committee. Int J Clin Pract*, 65 (6) 649-57, 2011. No IF
- 14) Reversible and non-reversible cardiovascular risk in patients treated with lipid-lowering therapy: analysis of SEAS and JUPITER trials. Poli A, Corsini A. *Eur J Intern Med* 2010 Oct; 21(5): 372-3. (IF 1.657)
- 15) Global cardiovascular risk management in different Italian regions: an analysis of the evaluation of final feasible effect of control training and ultra sensitisation (EFFECTUS) educational program. Tocci G, Ferrucci A, Guida P, Corsini A, Avogaro A, Comaschi M, Cortese C, Giorda CB, Manzato E, Medea G, Mureddu GF, Titta G, Ventriglia G, Riccardi G, Zito GB, Volpe M. *Nutr Metab Cardiovasc Dis*, December 24th, 2010 no IF
- 16) Do structural differences in statins correlate with clinical efficacy? Arnaboldi L, Corsini A. *Curr Opin Lipidol* 2010 (Aug); 21(4): 298-304. IF 6.636
- 17) Role of polymorphonuclear neutrophils in atherosclerosis: current state and future perspectives. Baetta R, Corsini A., *Atherosclerosis* 2010 (May); 210 (1): 1-13. IF 4.086

- 18) Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol. Corsini A, Windler E, Farnier M. *Eur J Cardiovasc Prev Rehabil.* 2009 Feb;16(1):1-9 IF: 2.515
- 19) EFFECTUS Steering Committee. Association of physicians' accuracy in recording with quality of care in cardiovascular medicine. Giorda CB, Guida P, Avogaro A, Cortese C, Mureddu GF, Corsini A, Comaschi MA, Manzato E, Volpe M, Zito GB, Medea G, Ventriglia G, Titta G, Riccardi G. *Eur J Cardiovasc Prev Rehabil* 2009 Dec; 16(6): 722-8. No IF
- 20) Drug-drug interactions with statins. Corsini A, Bellosta S. *Exp Rev Clin Pharmacol* 1 (1): 105-113, 2008 noIF
- 21) Are pleiotropic effects of statins real? Corsini A, Ferri N, Cortellaro M. *Vasc Health Risk Manag*, 2007; 3 (5): 611-3. no IF
- 22) Biomarkers for atherosclerosis: pathophysiological role and pharmacological modulation. Ferri N, Paoletti R, Corsini A. *Curr Opin Lipidol*, 17 (5): 495-501, 2006 IF 5.689
- 23) Hypolipidemic therapy for the metabolic syndrome. Cignarella A., Bellosta S, Corsini A, Bolego C. *Pharmacol. Res.* 53 (6): 492-500, 2006. IF 2.421
- 24) Fluvastatin treatment is not associated with an increased incidence of cancer. Stein EA, Corsini A, Gimpelewicz CR, Bortolini M, Gil M. Fluvastatin treatment is not associated with an increased incidence of cancer. *Int J Clin Pract.* 60 (9): 1028-34, 2006. IF 1.188
- 25) Statin-related muscle complaints: an underestimated risk. Corsini A. *Cardiovasc Drugs Ther.* 2005 Dec;19(6):379-81. IF 1.396
- 26) Pharmacokinetic interactions between statins and fibrates. Corsini A, Bellosta S, Davidson MH. *Am J Cardiol.* 2005 Nov 7;96(9A):44K-49K; discussion 34K-35K IF 3.015
- 27) Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Ferri N, Paoletti R, Corsini A. *Biomarkers.* 2005 Jul-Aug;10(4):219-37 IF 2.203
- 28) The use of statins in optimising reduction of cardiovascular focus on fluvastatin. Corsini A. *Int J Clin Pract.* 2004 Maggio;58(5):494-503 IF 1.223
- 29) Fluvastatin: Clinical and Safety Profile. Corsini A, Jacobson T.A, Ballantyne C.M. *Drugs* 2004;64(12):1305-23 I.F. 5.368
- 30) Safety of Statins: Focus on Clinical Pharmacokinetics and Drug Interactions. S. Bellosta, R. Paoletti, A. Corsini. *Circulation* 2004 Jun 15;109(23 Suppl 1):III50-7 I.F. 10.255
- 31) The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk A. Corsini. *Cardiovascular Drugs and Therapy* 2003;17:257-297 I.F. 0.908
- 32) Risk for myopathy with statin therapy in high-risk patients Christie M. Ballantyne, Alberto Corsini, Michael H. Davidson, Hallvard Holdaas, Terry A. Jacobson, Eran Leitersdorf, Winfried Marz, John P.D. Reckless, Evan A. Stein *Archives of Internal Medicine* 2003;163:553-564 I.F. 6,661

- 33) Safety considerations for statins. C. Bolego, R. Baetta, S. Bellosta, A. Corsini, R. Paoletti
Current Opinion in Lipidology 2002; (13):637-644 I.F. 7,028
- 34) Pharmacological interactions of statins. R Paoletti, A Corsini, S Bellosta. Atherosclerosis
Supplement 2002; Maggio Vol. 3 : 35 - 40 I.F. 16,25
- 35) Clinically relevant pleiotropic effects of statins: drug properties or effect of profound cholesterol
reduction? Comparato C, Altana C, Bellosta S, Baetta R, Paoletti R, Corsini A. Nutrition
Metabolism Cardiovascular Disease 2001;11:328-343 I.F. 1,123
- 36) Non-lipid-related effects of statins. Bellosta S, Ferri N, Bernini F, Paoletti R, Corsini A. Ann
Med 2000, 32: 164-176 I.F. 2,794
- 37) Pleiotropic effects of statins in atherosclerosis and diabetes. Bellosta S, Ferri N, Bernini F,
Corsini A. Diabetes Care 2000; 23(suppl. 2):B72-B78. I.F. 4,992
- 38) New insights into the pharmacodynamics and pharmacokinetic properties of statins. Corsini A,
Bellosta S, Baetta R, Fumagalli R, Paoletti R, Bernini F. Pharmacology and Therapeutics 1999;
84: 413-428. I.F. 7,711
- 39) Non-lipid-related effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
Corsini A, Bernini F, Qaurato P, Donetti E, Bellosta S, Fumagalli R, Paoletti R, Soma MR.
Cardiology, 1996; 87: 458-468. I.F. 0,538
- 40) Pharmacology of competitive inhibitors of HMG-CoA reductase. Corsini A, Maggi FM,
Catapano AL. Pharm. Res., 1995; 31: 9-27 IF 0,71

TOTALE PUBBLICAZIONI (SCOPUS)	209
NUMERO TOTALE DI CITAZIONI (SCOPUS)	5596
MEDIA CITAZIONI PER LAVORO	26,77
INDICE DI HIRSCH	41

ORGANIZZAZIONE DI CORSI O CONGRESSI

- 2013** Coordinatore scientifico del corso biosimilari in emato-oncologia, Mantova
- 2012** Coordinatore scientifico del corso di farmacologia clinica in oncologia, Mantova
- 2009** Ruolo della farmacocinetica nello sviluppo dei farmaci, Milano, Febbraio
- 2008** Membro del comitato scientifico dell'Int. Congress on multiple risk factors, Venice
- 2007 -** Segretario Scientifico del Corso di Farmacocinetica
"Considerazioni di farmacocinetica e di farmacologia clinica nell'anziano"
Milano, 2 Febbraio
- 2005 -** Segretario Scientifico del Corso di Farmacocinetica
"Ruolo dei trasportatori proteici nella cinetica dei farmaci"
Corso di aggiornamento in farmacocinetica
Milano, 10 Febbraio
- 2004 -** Segretario Scientifico del Corso di Farmacocinetica
"Volume di distribuzione, interazione farmaco proteica, clearance: parametri
fondamentali in farmacocinetica"
Corso di aggiornamento in farmacocinetica
Milano, 10 Febbraio
- 2002 -** Segretario Scientifico del Corso di Farmacocinetica
"Dal drug discovery al complesso problema delle interazioni"
Corso di aggiornamento in farmacocinetica
Milano, 6-8 Febbraio
- Segretario Scientifico del Congresso "Global risk of coronary heart disease and
stroke: Assessment, Prevention, and Treatment"
Firenze, 12-15 Giugno
- Membro dell'Advisory Bord del XIIth International Vascular Biology Meeting
Karizawa, Giappone
- 2001 -** Segretario Scientifico del Congresso "Attualità ed orientamenti
farmaco terapeutici in oncologia"
Milano, 27 Ottobre
- Segretario Scientifico del Corso di Farmacocinetica "Sinergismo tra
biofarmaceutica e farmacocinetica: correlazioni in vitro-in vivo"
Milano, 6 Febbraio
- 2000 -** Segretario Scientifico del Corso Internazionale "Therapy and
prevention of cardiovascular disease: hypolipidemic drugs"
Lugano, Svizzera, 12-14 Ottobre
- Segretario Scientifico del Corso di Farmacocinetica
"La Farmacocinetica nella ricerca, sviluppo e registrazione dei farmaci"

Milano, 7-9 Febbraio

- Membro dell' "Advisory Bord" del XIth International Vascular Biology Meeting
Ginevra, Svizzera, 5-9 Settembre
- 1999** - Segretario Scientifico del II° Incontro di Aggiornamento sugli "Aspetti Farmacologici e Tossicologici delle Terapie Oncologiche"
Milano, 29-30 Giugno
- Membro del Comitato Scientifico del Corso di Perfezionamento in Registrazione Europea dei Farmaci
Milano, Maggio-Giugno
Venezia, 28-31 Ottobre
- 1998** - Segretario Scientifico del Corso di Farmacocinetica "Fondamenti di Farmacocinetica: dalla teoria alla pratica clinica"
Milano, 16-18 Giugno
- Membro del Comitato Organizzativo del "XIII International Symposium on Drugs Affecting Lipid Metabolism"
Firenze, 30 Maggio-3Giugno
- Membro del Local Committee al "5th International Symposium. Multiple Risk Factors in Cardiovascular Disease Global Assessment and Intevention"
Venezia, 28-31 Ottobre
- 1996** - Membro del Comitato Scientifico del "66th Congress of the European Atherosclerosis Society
Firenze, 13-17 Luglio
- 1993** - Membro del Comitato Organizzativo del "International Symposium on the Lipid Triad (Triglycerides, HDL, LDL) and Cardiovascular Diseases"
Milano, 5-8 Luglio
- 1992** - Membro del Comitato Organizzativo del "XI International Symposium on Drugs Affecting Lipid Metabolism"
Firenze
- 1991** - Segreteria Scientifica del Congresso "Controllo Farmacologico dell'Interazione Piastrine-Pareti Vasali"
Milano
- Membro del Comitato Scientifico del Meeting su: "High Density Lipoprotein: Physiopathology and Clinical Relevance"
Bellagio (CO)
- 1990** - Membro del Comitato Organizzativo del Congresso "Triglycerides: the Role in Diabets and Atherosclerosis"
Vienna, Austria

CONTRIBUTI PER LE RICERCHE SPERIMENTALI:

- 2014** Titolare del progetto di ricerca “Studies on the hypocholesterolemic effect of P-3083: “in vitro” pharmacological approach” (Polichem)
- 2014** Titolare del progetto di ricerca “Administration of Legalon Plus in a rat model of nonalcoholic hepatic steatosis: evaluation of its anti-inflammatory, antioxidant, antifibrotic and liver lipid-lowering effects” (Rottapharm)
- 2013** Titolare del progetto di ricerca “CARIPLO Foundation” Italy on Investigating the role of pro-protein convertase subtilisin/kexin type 9 (PCSK9) released from smooth muscle cells on atherogenesis” (2012-0549)
- 2013** Titolare del progetto di ricerca “Administration of Legalon Plus in a rat model of nonalcoholic hepatic steatosis: evaluation of its anti-inflammatory, antioxidant, antifibrotic and liver lipid-lowering effects” (Rottapharm Università degli Studi di Milano)
- 2010** Titolare del progetto di Ricerca “Everolimus in de Novo Heart Transplant Recipients (EVERHEART)” (Novartis – Università degli Studi di Milano)
- 2009** Titolare del progetto di ricerca PRIN 2009 “Sintesi e caratterizzazione farmacologica di composti ibridi antiproliferativi e donatori di NO: una nuova strategia per il controllo dell'aterosclerosi”
- 2008** Titolare del progetto di ricerca “L’effetto di aliskiren sull’espressione e sull’attività del recettore della (pro)renina” (Novartis – Università degli Studi di Milano)
- 2005** Titolare del progetto di ricerca “Drug Design for Cardiovascular Diseases: Integration of in Silico and in Vitro Analysis“ (FP6; LIFE SCIENCES, GENOMICS AND BIOTECHNOLOGY FOR HEALTH)
- 2005** Titolare del progetto di ricerca su: Antiatherothrombotic effects of everolimus alone or in combination with fluvastatin: “in vitro” and “in vivo” studies” (Novartis – Università degli Studi di Milano)
- 2003** Titolare del progetto di ricerca su: “A Randomized, Double-Blind, Double-Dummy Two-Way Crossover Study to assess the Effect of Sera from Patients treated with Fluvastatin XL (80 mg) and Fluvastatin IR (40 mg b.i.d.) on Human Cultured Arterial Myocyte Proliferation and Possibile mechanism(s) ” Novartis - Università degli Studi di Milano – Centro E. Grossi Paoletti)

Collaboratore al programma di ricerca FIRB “Nuove strategie per la prevenzione e il controllo dell'ischemia cerebrale su base vascolare: ruolo dei meccanismi infiammatori e proteolitici“ (Università degli Studi di Parma - Università degli Studi di Milano)

Collaboratore al programma di ricerca “Disegno e sintesi di composti per l’inibizione di enzimi coinvolti in maniera specifica nel controllo della proliferazione delle cellule tumorali” (Istituto di Chimica Organica “Alessandro Marchesini”-Università degli Studi di Milano)

- 2002** Collaboratore al programma di ricerca “Effetto del losartan e dell’acido urico sui meccanismi cellulari dell’aterogenesi” (Sigma-Tau (Roma)-Università degli Studi di Parma e degli Studi di Milano)
- Titolare del progetto di ricerca su: “Studies on the pleiotropic effect of rosuvastatin: is liver the main target?” (Astra Zeneca- Inghilterra - Università degli Studi di Milano)
- 2001** Titolare del progetto di ricerca FIRST su: “Ruolo delle proteine prenilate nell’aterogenesi e potenziali implicazioni farmacologiche”
- Titolare del progetto di ricerca su: “Antiatherothrombotic properties of rosuvastatin in Apo E-deficient mice” (Astra Zeneca – Inghilterra – Università degli Studi di Milano)
- Titolare del progetto di ricerca “Raloxifene effect on the inflammatory and atherogenic profile of arterial intimal lesion in ovariectomized, cholesterol-fed rabbits” (Eli Lilly – Indianapolis, Indiana (USA) – Università degli Studi di Milano)
- 2000** Titolare del progetto di ricerca “Controllo farmacologico delle proteine prenilate nella regolazione della proliferazione dei miociti vasali” (ex MURST 60% 2000)
- Titolare del progetto di ricerca “Studies on the antiatherosclerotic mechanisms of lacidipine” (Glaxo Wellcome SpA – Verona – Università degli Studi di Milano)
- Titolare del progetto di ricerca “Valutazione degli effetti di lercanidipina associata a simvastatina sulla biosintesi del colesterolo in miociti umani” (Recordati – Milano – Università degli Studi di Milano)
- Titolare del progetto di ricerca “Effect of lercanidipine racemate and (R) enantiomer on neointimal hyperplasia induced by perivascular manipulation of rabbit carotid arteries” (Recordati – Milano – Università degli Studi di Milano)
- 1999** Coordinatore nazionale del progetto di ricerca “Ruolo delle cellule muscolari lisce nell’aterogenesi: implicazioni farmacologiche” (MURST Cofinanziamento 99)
- Titolare del progetto di ricerca: "Potenziali effetti sinergistici del calcio antagonista lercanidipina con l'inibitore della HMG-CoA riduttasi sulla migrazione e proliferazione delle cellule muscolari lisce vasali” (Recordati S.p.A. – Italia – Università di Milano)
- 1998** Titolare del programma di ricerca su: “Effetti del valsartan sulla migrazione e sulla modulazione del fenotipo delle cellule muscolari lisce” (Novartis Pharma - Basilea - Università di Milano)
- 1997** Titolare del programma di ricerca su “Studio sulla potenziale attività antiaterosclerotica di Fluvastatina: ”Effetti sulla metalloproteinasi di matrice in colture cellulari. Studi in vitro” (Sandoz Prodotti Farmaceutici - Basilea - Università di Milano)
- 1996-1998** Collaboratore al programma di ricerca “La via metabolica del mevalonato e l’isoprenilazione di proteine cellulari come bersagli nel controllo farmacologico della replicazione dei miociti vasali” Finanziato dal Consiglio Nazionale delle Ricerca presso l’Istituto di Scienze Farmacologiche, dell’Università di Milano

- 1996-1998** Collaboratore al programma di ricerca “Ciclo cellulare apoptosi” Finanziato dal Consiglio Nazionale delle Ricerca presso l’Istituto di Scienze Farmacologiche, dell’Università di Milano
- 1995** Responsabile del programma di ricerca su “Proprietà farmacologiche degli inibitori della farnesil e geranilgeranil transferasi nell’aterosclerosi e nei tumori” (Istituto di Ricerche Servier - Parigi - Università di Milano)
- 1994-1996** Collaboratore al programma di ricerca “Controllo farmacologico degli isoprenoidi nella regolazione della proliferazione dei miociti vasali” Finanziato dal Consiglio Nazionale delle Ricerca presso l’Istituto di Scienze Farmacologiche, dell’Università di Milano
- 1990-1995** Collaboratore al programma di ricerca “Caratterizzazione dei difetti molecolari in cellule di pazienti affetti da ipercolesterolemia o da patologie del connettivo” Finanziato dal Consiglio Nazionale delle Ricerca presso l’Istituto di Scienze Farmacologiche, dell’Università di Milano
- 1990-1992** Collaboratore al programma di ricerca “Canali del calcio, recettori LDL e prostanoidi nei macrofagi” presso l’Istituto di Scienze Farmacologiche, dell’Università di Milano
- 1986** Collaboratore al programma di ricerca “Determination of the functional domains in apolipoprotein B-100” Finanziato da U.S. Public Health Service, National Institute of Health, presso la Gladstone Foundation, San Francisco, (U.S.A.)
- 1982-1984** Collaboratore al programma di ricerca “Meccanismi biologici dell’azione antiaterosclerotica dei glicosaminoglicani” Finanziato dal Ministero della Pubblica Istruzione presso l’Istituto di Scienze Farmacologiche, dell’Università di Milano.

SEMINARI DI RICERCA

- 2004** - Seminario presso Centre de Biochimie INSERM, Nice cedex (France)
“Experimental models of atherosclerosis and their pharmacological control”
- Seminario presso Centro di Ricerche Farmacologiche per lo Studio e la Prevenzione delle Malattie Cardiovascolari – Centro Cardiologico Monzino, Milano
“Effetti pleiotropici delle statine: mito o realtà?”
- 2001** - Seminario presso Centre de Recherche en Cardiologie – Université Catholique De Louvain
Bruxelles, Belgio
- “New insights into the pharmacodynamic and pharmacokinetic properties of statins”
- Seminario presso Institut de Reserchers Servier
“Infiltration of polymorph nuclear leukocytes and interaction with vascular smooth muscle cells in atherogenesis: pharmacological implications”
Parigi, Francia
- 2000** Seminario presso LMRC, Brigham & Women’s Hospital, Harvard Medical School

Boston, USA

“Pharmacological control of Protein Prenylation: Effect on Arterial Smooth Muscle Cell Proliferation”

- Seminario presso J. David Gladstone Institute, San Francisco, California, USA
"Role of prenylated proteins in arterial smooth muscle cell proliferation and their pharmacological modulation"

1999

Seminario presso il Centro di Biotecnologie Avanzate
"Ruolo delle proteine prenilate nella proliferazione cellulare e loro controllo farmacologico"
Genova, Italia

1998

Seminario al Dipartimento di Patologia, Ospedale Cantonale Università di Ginevra
“The role of prenylated proteins in the control of smooth muscle cell proliferation and their pharmacological modulation”
Ginevra, Svizzera

1997

Seminario presso Department of Medicine Division of Metabolism, Endocrinology and Nutrition, Seattle, Washington, USA: “Modulation of the mevalonate pathway: effects on cell metabolism”

- Seminario presso J. David Gladstone Institutes, San Francisco, California, USA: “Effects of HMG-CoA reductase inhibitors on the regulatory pathway controlling the G1 phase of the cell cycle”

1996

Seminario presso J. David Gladstone Institutes, San Francisco, California, USA: “Pharmacological control of protein prenylation and cell proliferation”

Seminario presso l’Istituto di Scienze Farmacologiche:
“Ruolo delle proteine isoprenilate nella proliferazione cellulare e loro controllo farmacologico”

1995

Seminario presso J. David Gladstone Institutes, San Francisco, California, USA: “Role of prenylated protein(s) in the control of cell proliferation”

1994

Seminario presso la New York University, Department of Surgery and Medicine, New York, USA.

"Cholesterol homeostasis and arterial myocyte proliferation"

Seminario presso l’Istituto di Scienze Farmacologiche:
“Ruolo della via metabolica del mevalonato nei processi di crescita cellulare”

1993

Special Lecture presso la New York Hospital-Cornell Medical Center, New York, USA.

"Relationship between mevalonate pathway and arterial smooth muscle cell proliferation: studies with inhibitors of HMG-CoA reductase"

Seminario presso il Department of Pathology, School of Medicine, University of Washington, Seattle, USA:

“Relationship between the mevalonate pathway and arterial myocyte proliferation”

Seminario presso J. David Gladstone Institutes, San Francisco, USA:

“Relationship between the mevalonate pathway and arterial myocyte proliferation”

1990 Gladstone Foundation Laboratories for Cardiovascular Disease 10th Anniversary; San Francisco, USA.
"Familial defective apolipoprotein B-100: characterization of an Italian family"

1987 Seminario presso San Francisco General Hospital, University of San Francisco, USA:
“Receptor binding of apo B-100 fragment”

Seminario presso Istituto di Scienze Farmacologiche, Milano:
“Espressione del gene della apoproteine E in colture cellulari”

1986 Seminario presso “J. David Gladstone Foundation Laboratories for Cardiovascular Disease; University of California, San Francisco, USA”
“Autoantibodies that impair LDL receptor binding in a subject affected by severe hypercholesterolemia”
“ Modulation of HDL binding to culture cells. Effects of cholesterol and hormones”

1984 Riunione Scientifica dell’Istituto di Farmacologia e Farmacognosia
Milano, 30 Novembre:
“Evidenziazione di una componente plasmatica che inibisce il metabolismo delle lipoproteine LDL in un soggetto ipercolesterolemico di tipo IIa”

International papers without referees

1. Results of the Heart Protection Study: can we still assume a class effect? A. Corsini, F. Bernini. International Congress Series (ICS) 2003;1841:1-7
2. Direct Vascular effects of HMG-CoA reductase inhibitors. Bellosa S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A. Atherosclerosis 1998; 137 Suppl. S101-S109
3. Pharmacology of competitive inhibitors of HMG-CoA reductase. Corsini A, Maggi FM, Catapano AL. Pharm. Res., 1995; 31: 9-27
4. Pathogenesis of atherosclerosis and the role of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R. Am. J. Cardiol., 1995; 76: 21A-28°
5. Cholesterol and mevalonic acid modulation in cell metabolism and multiplication. Soma MR, Corsini A, and Paoletti R. Toxicol. Lett. 1992; 64/65: 1-15
6. Effect of calcium antagonists on lipids and atherosclerosis. F Bernini, AL Catapano, A Corsini, R Fumagalli, R Paoletti Am. J. Cardiol. 1989; 64, 129I-134I

ARTICOLI SU RIVISTE SENZA REVISORI

1. The new calcium antagonist lercanidipine and its enantiomers affect major processes of atherogenesis *in vitro*: is calcium entry involved? Corsini A, Accomazzo MR, Canavesi M, Sartani Testa R, Catapano AL, Fumagalli R, Paoletti R, Bernini F. *Blood Pressure*, 1998; 7(Suppl 2): 1-5
2. Cerivastatin: Viewpoints. Corsini A. *Drugs*, 1998; 55 n.3: 421
3. Contrôle pharmacologique de la voie de biosynthèse du mévalonate: effet sur la prolifération de cellules musculaires lisses artérielle(*). Corsini A, Arnaboldi L, Quarato P, Ferri N, Granata A, Fumagalli R, Paoletti R. *Société de Biologie* 1997; 191: 169-194
4. Preclinical studies of fluvastatin Corsini A, Fumagalli R, Paoletti R, Bernini F. *Drugs of Today*, 1996; 32: 19-38
5. Introduction, principles of therapeutics of fluvastatin. Corsini A, Fumagalli R, Paoletti R, Soma M. *Drugs of Today*, 1996; 32: 9-18
6. Pharmacology of lipoprotein receptors. F Bernini, A Corsini, R Fumagalli, R Paoletti. *J. Lipid Med. Cell Sign.*1994; 9: 9-17
7. Experimental and clinical effects of isradipine relevant to atherosclerosis. Bernini F, Soma MR, Corsini A, Paoletti R. *Am. J. Hypertens.* 1994; 7: 30S-34S
8. Effects of lacidipine on experimental models of atherosclerosis. Bernini F, Corsini A, Raiteri M, Soma MR, Paoletti R. *J. Hypertens.* 1993; 11 (Suppl. 3): S61-S66
9. Effect of trapidil derivative AR12456 on intracellular cholesterol homeostasis in human hepatoma cell line Hep G2. Corsini A, Grignaffini P, Beitz J, Mest HJ, Bellosta S, Fumagalli R, Paoletti R. *Cytotechnology*, 1993; 11: S15-S17
10. High density lipoproteins: physiopathology and clinical relevance. A Corsini, F Bernini, C Vergani, AL Catapano. *Atherosclerosis* 1992, 92: 261-264

CAPITOLI

1. History and development of HMG-CoA reductase inhibitors. Bellosta S, Paoletti R, Corsini A. *Milestones in Drug Therapy* 2002; HMG-CoA Reductase Inhibitors:1-17
2. Incorporation of Radiolabeled Prenyl Alcohols and Their Analogs into Mammalian Cell Proteins. A. Corsini, C.C. Farnsworth, P. McGeedy, M.H. Gelb, J.A. Glomset. *The Protein Protocols Handbook*, 2nd Edition, 2002:641-656
3. Phenotypic Heterogeneity Influences Apoptotic Susceptibility to Retinoic Acid and cis-Platinum of Rat Arterial Smooth Muscle Cells In Vitro. Orlandi A, Francesconi A, Cocchia D, Corsini A, Spagnoli LG. *Arterioscler Thromb Vasc Biol* 2001;21:1118-1123
4. Effects of statins beyond lowering cholesterol : where do we stand. Quarato P, Ferri N, Arnaboldi L, Fumagalli R, Paoletti R, Corsini A. In: "Multiple risk factors in cardiovascular disease" (eds), Kluwer Academic Publishers, 1998; pp. 253-265
5. Drugs protecting the arterial wall. Bernini F, Corsini A, Bellosta S, Donetti E, Soma M, Paoletti R. In: "Drugs Affecting Lipid Metabolism", Gotto AM, jr., Paoletti R, Smith LC, Catapano AL (eds.), Kluwer Academic Publishers, 1996; pp. 17-26
6. Role of isoprenoids in the growth-factor signal transduction and their pharmacological modulation. Quarato P, Ferri N, Rudy L, Paoletti R, Fumagalli R, Corsini A. In: "Drugs Affecting Lipid Metabolism", Gotto AM, jr., Paoletti R, Smith LC, Catapano AL (eds.), Kluwer Academic Publishers, 1996; pp. 103-110
7. Insulin modulates the binding of high density lipoproteins to cultured human skin fibroblasts. A Corsini, R Fumagalli, AL Catapano. In: "Atherosclerosis Reviews. High Density Lipoproteins: Physiopathology and Clinical Relevance", (Gotto AM, Jr., Paoletti R, eds.), 1993, vol. 24 p. 111-118
8. Causes underlying the reduced response to simvastatin treatment in hypercholesterolemic patients. A Corsini, M Mazzotti, T Zanelli, P Uboldi, D Sommariva, F Pazzucconi, CR Sirtori, A Gaddi, G Descovich, A Granata, R

- Fumagalli, AL Catapano. In: NATO-ASI Series, "Human Apolipoprotein Mutants III. Diagnosis and Treatment" (C.R. Sirtori, G. Franceschini, B.H. Brewer, Jr., eds.) 1993, vol. 73, pp. 207-229
9. Abnormalities of apolipoprotein B metabolism in the lipid clinic. Corsini A, Catapano AL, Mazzotti M, Franceschini G, Romano C, Fumagalli R, Sirtori CR. In: "NATO-ASI" Series, "DNA polymorphisms as Disease Markers" 1991. D.J. Galton and G. Assmann, eds., Plenum Press, vol. 214: pp. 79-89
 10. Increased HDL₃ binding to cultured fibroblasts from a patients with familial hypoalphalipoproteinemia. A Corsini, A Granata, F Maggi, C Vergani, AL Catapano, R Fumagalli. In: "Atherosclerosis Reviews", "Biotechnology of Dyslipoproteinemias", Eds. A.M. Gotto, Jr., R. Paoletti, Raven Press, 1990; Vol. 20, pp. 109-118
 11. The control of dyslipoproteinemias: ways and means. R Paoletti, A Corsini. In: "Atherosclerosis Reviews", "Biotechnology of Dyslipoproteinemias", eds. A.M. Gotto, Jr., R. Paoletti, Raven Press, 1990; vol 20: pp. 159-170
 12. Effects of trapidil and its derivatives on the receptor-mediated low density lipoprotein metabolism by cultured human hepatic and extrahepatic cells. A Corsini, J Beitz, S Bellosta, F Bernini, R Fumagalli, HJ Mest, R Paoletti. In: Proceedings of the VII Atherosclerosis Cardiovascular Disease Conference (Descovich G.C. ed.) Kluwer Academic Publishers, Dor Drecht, The Netherlands 1991: pp 468-476
 13. Further studies with (5E) and (5Z) analogues of PGI₂ in platelets and vasculature. D Oliva, S Giovanazzi, M Lograno, N Mongelli, A Corsini, R Fumagalli, S Nicosia. In: "Advances in Prostaglandin, Tromboxane and Leukotriene Research" Raven Press, 19, 172-175, 1989
 14. Regulation of lipoprotein receptor activity in cultured cells: modulation by cholesterol and 26-hydroxycholesterol. A Corsini, S Bellosta, F Bernini, A Granata, AL Catapano, R Fumagalli In: Biomembranes et Nutrition, Leger C.L. e Bereziat G. eds., 1989 Inserm Edition, Vol. 195, pp. 333-344
 15. Calcium antagonists and low density lipoprotein receptors. R Paoletti, F Bernini, R Fumagalli, M Allorio, A Corsini Ann. New York Acad. Sci., 522, 390-398, 1988
 16. PGI₂ receptors in vascular and platelets: 5Z-carbacyclin discriminates between them. S Nicosia, D Oliva, MA Noe', A Corsini, GC Folco, R Fumagalli In: "Advances in Prostaglandin, Tromboxane and Leukotriene Research", Vol. 17 (R. Paoletti, P.V. Ramwell and B. Samuelsson, eds.), Raven Press, 474-478, 1987

PUBBLICAZIONI ITALIANE

1. Confermata l'efficacia della doppia inibizione Corriere Medico 2004;10 giugno: 9. Corsini A.
2. Antagonisti recettoriali dell'angiotensina II: uguali o diversi? M.D. Medicine Doctor 2003;3 dicembre, Anno X numero 36. Corsini A.
3. Efficacia e sicurezza della terapia con statine nel paziente ad alto rischio cardiovascolare. Corsini A, Canadesi M, Bernini F. Practicing Medicine (periodico di informazione e management) 2003; Vol 9: 1-24
4. Possiamo ancora parlare di effetto di classe dopo lo Heart Protection Study? A. Corsini, F. Bernini Cardiology Science 2003:1-4
5. Un nuovo approccio al controllo del rischio cardiovascolare Corsini A. Ann Ital Med Int 2003, Vol 18 (Suppl 3):65S-72S
6. La doppia inibizione: una nuova strategia per il controllo dell'ipercolesterolemia. Corsini A. M.D. Medicinae Doctor 2003, Anno X – Numero 37, 10 Dicembre: 36-37
7. La doppia inibizione: una nuova strategia terapeutica per il controllo dell'ipercolesterolemia. Corsini A. MeDia 2003;3:242-244
8. Interazioni tra farmaci. Corsini A, Fumagalli R. La Farmaco Terapia 2002; 137-173
9. La rabdiomiolisi. Corsini A, Bellosta S Ann Ital Med Int, 2002; 17:146-148

10. Le statine: Farmacologia e clinica. A Corsini, F Bernini. *Farmaci* 2002; Vol 26 n.3:1-24
11. Efficacia e sicurezza della terapia con statine. Bellosta S, Corsini A. *Iperlipidemie*. InterScience Publishing, 2001; 105-116
12. Efficacia e tollerabilità delle statine: nuovi dati Corsini A, Paoletti R, Bellosta S *Annali Italiani di Medicina Interna*. 2000 Vol 15 (Suppl. 1):106S-111S
13. Gli ipocolesterolemizzanti protettori di parete. Corsini A, Paoletti R, Bellosta S. *Atti del VIII Congresso Nazionale di Siena: I fattori di rischio aterogeno*. 2000:121-142
14. Aterosclerosi. Paoletti R, Corsini A, Poli A, Catapano AL. In: "Enciclopedia del corpo umano", Vol. II, Treccani Ed. "L'universo del corpo" Vol II 1999; 327-340
15. Effetto di parete dei farmaci ipolipidizzanti. Corsini A, Quarato P, Arnaboldi L. *Atti del corso di Patologia 6° corso; Fondazione Guido Murati* 1998: 95-125
16. Statine e placca ateromasica: al di là dell'effetto ipocolesterolemizzante. Corsini A, Bellosta S, Quarato P. *Cardiologia* 1998; 32° Convegno Internazionale del Dipartimento Cardiologico e Cardiochirurgico A. De Gasperis 1999: 499-507
17. I nuovi trials sulle strategie ipocolesterolemizzanti. Corsini A, Arnaboldi L, Olgiati PMG *Life Sciences Cardiology* 1999; Anno II n. 2: 3-9
18. Inibitori delle COMT: caratteristiche farmacocinetiche ed effetti sul metabolismo energetico. Corsini A, Bellosta S. *Profili Terapeutici & Farmacologici* 1999; Suppl. n. 10 a *Drug Outline*: 3-38
19. La terapia delle iperlipidemie: effetti delle statine su fattori non lipidici Bellosta S, Corsini A. *Iperlipidemie*. InterScience Publishing, 1999; 125-135
20. Dislipidemie. Corsini A, Romano L, Catapano AL In "Malattie genetiche" McGraw-Hill Libri Italia, 1998; 15: 127-145
21. Assorbimento dei farmaci, vie di somministrazione, biodisponibilità . Fumagalli R, Corsini A. *U.T.E.T. Farmacologia Clinica* 1998; 1-12
22. Testosterone e metabolismo lipidico. Arnaboldi L, Quarato P, Ferri N, Fumagalli R, Corsini A. *Aggiornamento Medico Suppl. 10* 1997: 65-73
23. Effetti antiaterosclerotici della lacidipina. Soma MR, Corsini A, Bernini F *Agorà* 1995; 8: 23-32
24. Nuove conoscenze sul metabolismo del colesterolo: colesterolo legato alle lipoproteine LDL ed alle lipoproteine HDL. A. Corsini, R. Paoletti. In: *Giornate Cardiologiche Romane* 1990, pp. 122-126
25. Correlazione tra il potenziale irritante di tensioattivi in vivo e la loro attività citotossica. M Marinovich, B Viviani, E Tragni, A Corsini, A Granata, CL Galli. *Cosmesi Dermatologica*, 26, 35-46, 1989
26. La biologia molecolare del controllo del colesterolo. A Corsini, A Poli, R Paoletti. *Biotechnology Reports*, 2-4, 1988
27. Ipercolesterolemia familiare: studio del recettore per le LDL. Trattamento con plasmoferesi. C Bellini, E Bendioli, G Ruffo, E Franchini, L Rivabella, G Cinollo, AL Catapano, R Fumagalli, A Corsini, G Gemme. *Minerva Pediatrica*, 38, 893-902, 1986